Literature DB >> 11994761

CD44 variant exons in leukemia and lymphoma.

Elif Akisik1, Sevil Bavbek, Nejat Dalay.   

Abstract

CD44 is a cell surface glycoprotein expressed on different cell types that functions in lymphocyte activation and homing, extracellular matrix adhesion and cellular migration. CD44 is encoded by a single gene composed of at least 20 exons. The standard CD44 protein (CD44S or CD44H) is the hematopoietic form of CD44 in lymphoid cells. Variant isoforms (designated from v1 to v10) are formed by addition of new exons to the extracellular domain. High levels of CD44v6 expression has been observed in some tumors and are associated with metastatic spread. The aim of the present study was to investigate and evaluate expression of the CD44v6 and v6-containing variants as a possible marker in chronic myeloid leukemia and lymphoma by reverse transcription-polymerase chain reaction. CD44 exon v6 was detected in all patients and all individuals in the control group. CD44v6-v10 mRNA was observed in 25 patients but in none of the subjects in the control group. CD44v6/v9-10, CD44v6-v7, CD44v6/v10 transcripts were detected in 11, 6, and 2 patients, respectively. CD44v6-7/v9-10 transcripts were not observed in either the patients or the healthy individuals. We conclude that CD44v6-v10 expression may be associated with hematologic malignancies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11994761     DOI: 10.1007/bf03033699

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  49 in total

1.  Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas.

Authors:  T A Tran; B V Kallakury; C E Sheehan; J S Ross
Journal:  Hum Pathol       Date:  1997-07       Impact factor: 3.466

Review 2.  The CD44 proteins in embryonic development and in cancer.

Authors:  L Sherman; J Sleeman; P Dall; A Hekele; J Moll; H Ponta; P Herrlich
Journal:  Curr Top Microbiol Immunol       Date:  1996       Impact factor: 4.291

3.  Expression of proliferating cell nuclear antigen and CD44 variant isoforms in the primary and metastatic sites of nonsmall cell lung carcinoma with intrapulmonary metastases.

Authors:  T Fukuse; T Hirata; H Naiki; S Hitomi; H Wada
Journal:  Cancer       Date:  1999-10-01       Impact factor: 6.860

4.  Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor.

Authors:  T Hirata; T Fukuse; H Naiki; S Hitomi; H Wada
Journal:  Cancer Res       Date:  1998-03-15       Impact factor: 12.701

5.  CD44v6 expression in non-Hodgkin's lymphoma: an association with low histological grade and poor prognosis.

Authors:  R Ristamäki; H Joensuu; K O Söderström; S Jalkanen
Journal:  J Pathol       Date:  1995-07       Impact factor: 7.996

6.  Expression of variant CD44-messenger RNA in colorectal adenocarcinomas and adenomatous polyps in humans.

Authors:  F Imazeki; O Yokosuka; T Yamaguchi; M Ohto; K Isono; M Omata
Journal:  Gastroenterology       Date:  1996-02       Impact factor: 22.682

7.  Participation in normal immune responses of a metastasis-inducing splice variant of CD44.

Authors:  R Arch; K Wirth; M Hofmann; H Ponta; S Matzku; P Herrlich; M Zöller
Journal:  Science       Date:  1992-07-31       Impact factor: 47.728

8.  Prevention of tumor metastasis formation by anti-variant CD44.

Authors:  S Seiter; R Arch; S Reber; D Komitowski; M Hofmann; H Ponta; P Herrlich; S Matzku; M Zöller
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

9.  CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor.

Authors:  R Stauder; W Eisterer; J Thaler; U Günthert
Journal:  Blood       Date:  1995-05-15       Impact factor: 22.113

10.  Regulated expression of exon v6 containing isoforms of CD44 in man: downregulation during malignant transformation of tumors of squamocellular origin.

Authors:  M Salmi; K Grön-Virta; P Sointu; R Grenman; H Kalimo; S Jalkanen
Journal:  J Cell Biol       Date:  1993-07       Impact factor: 10.539

View more
  15 in total

1.  Evaluation of some biochemical markers as prognostic factors in malignant lymphoma.

Authors:  Hisham Ismail; Mohamed A Soliman
Journal:  Int J Health Sci (Qassim)       Date:  2011-07

2.  Role of CD44 expression in non-tumor tissue on intrahepatic recurrence of hepatocellular carcinoma.

Authors:  Lkhagva-Ochir Tovuu; Satoru Imura; Tohru Utsunomiya; Yuji Morine; Tetsuya Ikemoto; Yusuke Arakawa; Hiroki Mori; Jun Hanaoka; Mami Kanamoto; Koji Sugimoto; Shuichi Iwahashi; Yu Saito; Shinichiro Yamada; Michihito Asanoma; Hidenori Miyake; Mitsuo Shimada
Journal:  Int J Clin Oncol       Date:  2012-06-16       Impact factor: 3.402

3.  CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway.

Authors:  Mayumi Jijiwa; Habibe Demir; Snehalata Gupta; Crystal Leung; Kaushal Joshi; Nicholas Orozco; Tiffany Huang; Vedat O Yildiz; Ichiyo Shibahara; Jason A de Jesus; William H Yong; Paul S Mischel; Soledad Fernandez; Harley I Kornblum; Ichiro Nakano
Journal:  PLoS One       Date:  2011-09-06       Impact factor: 3.240

Review 4.  Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy.

Authors:  Jennifer M Wickens; Hashem O Alsaab; Prashant Kesharwani; Ketki Bhise; Mohd Cairul Iqbal Mohd Amin; Rakesh Kumar Tekade; Umesh Gupta; Arun K Iyer
Journal:  Drug Discov Today       Date:  2016-12-23       Impact factor: 7.851

5.  LRP-1--CD44, a new cell surface complex regulating tumor cell adhesion.

Authors:  Gwenn Perrot; Benoit Langlois; Jérôme Devy; Albin Jeanne; Laurie Verzeaux; Sébastien Almagro; Hervé Sartelet; Cathy Hachet; Christophe Schneider; Emilie Sick; Marion David; Michel Khrestchatisky; Hervé Emonard; Laurent Martiny; Stéphane Dedieu
Journal:  Mol Cell Biol       Date:  2012-06-18       Impact factor: 4.272

Review 6.  CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?

Authors:  Margot Zöller
Journal:  Nat Rev Cancer       Date:  2011-03-10       Impact factor: 60.716

7.  Epithelial hyaluronic acid and CD44v6 are mutually involved in invasion of colorectal adenocarcinomas and linked to patient prognosis.

Authors:  Martin Köbel; Wilko Weichert; Katharina Crüwell; Wolfgang D Schmitt; Christine Lautenschläger; Steffen Hauptmann
Journal:  Virchows Arch       Date:  2004-09-16       Impact factor: 4.064

8.  CD44 splice variant (CD44v3) promotes progression of urothelial carcinoma of bladder through Akt/ERK/STAT3 pathways: novel therapeutic approach.

Authors:  Vivek Anand; Madhuram Khandelwal; Sandeep Appunni; Nidhi Gupta; Amlesh Seth; Prabhjot Singh; Sandeep Mathur; Alpana Sharma
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-16       Impact factor: 4.553

Review 9.  Hepatocyte nuclear factor (HNF)-1β and its physiological importance in endometriosis.

Authors:  Juria Akasaka; Chiaki Uekuri; Hiroshi Shigetomi; Matsuki Koike; Hiroshi Kobayashi
Journal:  Biomed Rep       Date:  2012-10-11

10.  Characterization and Functional Analysis of CD44v6.CAR T Cells Endowed with a New Low-Affinity Nerve Growth Factor Receptor-Based Spacer.

Authors:  Anna Stornaiuolo; Barbara Valentinis; Camilla Sirini; Cinzia Scavullo; Claudia Asperti; Dan Zhou; Yeny Martinez De La Torre; Stefano Corna; Monica Casucci; Simona Porcellini; Catia Traversari
Journal:  Hum Gene Ther       Date:  2021-05-05       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.